Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1382 participants.
Also called NCT06316570
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,382 participants
- Sponsor
- Registry
-
NCT06316570
-
- Other papers using this trial's data
- Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial
- Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06316570. Randomized; triple masking; primary purpose treatment. Start 2024-04-03 (actual); primary completion 2025-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke
- Acronym
- TAPIS
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Early Dual Antiplatelet Therapy
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct06316570- Content hash
c8cb84b57e198ed5f5d4852bfc5d21611ec9d3fb4800a962b60c4278554e7f8b